181 related articles for article (PubMed ID: 9674850)
1. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
Moreau P; Milpied N; Voillat L; Colombat P; Mahé B; Rapp MJ; Moreau A; Dupas B; Bulabois CE; Juge-Morineau N; Harousseau JL
Bone Marrow Transplant; 1998 Jun; 21(12):1193-6. PubMed ID: 9674850
[TBL] [Abstract][Full Text] [Related]
2. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
[TBL] [Abstract][Full Text] [Related]
3. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
5. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of non-Hodgkin's lymphoma].
Yamane T; Hino M; Ohta K; Koh KR; Nakamae H; Aoyama Y; Ota T; Kishida T; Mugitani A; Sannomiya Y; Kamitani T; Takubo T; Tatsumi N
Gan To Kagaku Ryoho; 2000 Sep; 27(10):1547-55. PubMed ID: 11016000
[TBL] [Abstract][Full Text] [Related]
6. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V
Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723
[TBL] [Abstract][Full Text] [Related]
7. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
[TBL] [Abstract][Full Text] [Related]
8. [High-dose therapy and peripheral blood stem cell transplantation for patients with aggressive non-Hodgkin's lymphoma remaining in initial remission: results of a feasibility study].
Kitajima H; Nasu K; Tsudo M; Fujimoto M; Hayashi K; Ohno H; Konaka Y; Katsurada T; Arima N; Doi S; Moriguchi T; Fukuhara S
Rinsho Ketsueki; 2001 Mar; 42(3):191-8. PubMed ID: 11345781
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Jantunen E; Mahlamäki E; Nousiainen T
Bone Marrow Transplant; 2000 Oct; 26(7):737-41. PubMed ID: 11042654
[TBL] [Abstract][Full Text] [Related]
11. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
[TBL] [Abstract][Full Text] [Related]
12. [Trial of front-line intensive chemotherapy followed by peripheral blood stem cell transplantation in high-intermediate and high risk non-Hodgkin's lymphoma patients].
Motomura S; Hashimoto C; Kodama F; Maruta A; Sakai R; Fujita H; Tomita N; Fujisawa S; Harano H; Koharazawa H; Fujimaki K; Kanamori H; Ishigatsubo Y
Rinsho Ketsueki; 2005 May; 46(5):350-7. PubMed ID: 16444968
[TBL] [Abstract][Full Text] [Related]
13. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
14. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
17. Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome.
Martín C; Torres A; León A; Rubio V; Alvarez MA; Herrera C; Jean-Paul E; Correa MA; Rojas R; Campos R; Serrano J; Romero R; Román J; Guzmán JL; Flores R; Falcón M; Martínez F; Gómez P
Bone Marrow Transplant; 1998 Feb; 21(4):375-82. PubMed ID: 9509972
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age.
Stamatoullas A; Fruchart C; Khalfallah S; Buchonnet G; Contentin N; Bastit D; Tilly H
Bone Marrow Transplant; 1997 Jan; 19(1):31-5. PubMed ID: 9012928
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
Weaver CH; Schwartzberg L; Rhinehart S; West J; Zhen B; West WH; Buckner CD
Bone Marrow Transplant; 1998 Feb; 21(4):383-9. PubMed ID: 9509973
[TBL] [Abstract][Full Text] [Related]
20. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
